Johnson & Johnson
JNJ
$255.56
+0.90%
Johnson & Johnson is the world's largest diversified healthcare company, operating through two segments — Innovative Medicine (pharmaceuticals focused on immunology, oncology, and neurology) and MedTech (surgical, orthopedic, and interventional devices) — following the 2023 spin-off of its consumer health business, Kenvue. The company's scale, AAA-rated balance sheet, and 60-plus-year dividend growth streak make it the archetypal defensive healthcare compounder, distinct from faster-growing pure-play biotechs and from device specialists that lack its pharmaceutical diversification. The current investor debate centers on whether J&J's oncology franchise and pipeline can offset MedTech softness and looming biosimilar erosion in immunology (notably Stelara), with recent Q3 results showing an earnings beat but a revenue miss that sent shares lower despite management raising full-year sales guidance. Bulls point to a path toward $100 billion in annual revenue and robust pharmaceutical momentum, while bears flag premium valuation, biosimilar competition, and persistent litigation costs.…
JNJ
Johnson & Johnson
$255.56
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating: Hold with a constructive bias. JNJ is a high-quality defensive compounder whose 33.0% one-year return has already captured much of the near-term upside, leaving only +9.3% to the $279.41 average analyst target against a consensus buy rating (mean 1.91 from 22 analysts). The thesis is that oncology-led Innovative Medicine growth and a fortress balance sheet justify owning the stock, but the current price already reflects most of that value.
Supporting evidence is solid: revenue grew 6.6% year-over-year to $25.31 billion in Q2 2026, operating margin recovered to 28.3% from 22.8% in Q4 2025, trailing free cash flow is $18.71 billion, and ROE is 32.9% — all well above industry norms. The 2.46% dividend yield with a 46.2% payout and 64-year increase streak provides income support, while the 18.8x trailing PE sits in the lower half of the stock's multi-year 9x-36x band. However, the 5.35x PS and 6.18x price-to-book are rich versus history, and the 21.8x forward PE exceeds the trailing multiple, signaling expected EPS normalization.
The biggest risks that could invalidate the thesis are accelerated Stelara biosimilar erosion, a prolonged MedTech slump, and a major litigation charge. This Hold would upgrade to Buy on a pullback toward the $230s (roughly 13x forward EPS) or on evidence that oncology growth is offsetting immunology losses faster than expected; it would downgrade to Sell if revenue growth decelerates below 4% or if forward EPS guidance is cut. Verdict: fairly valued to modestly rich relative to peers and its own history — a quality holding, not a bargain.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ is a high-quality defensive compounder that has already delivered 33.0% over the past year, and the current setup is balanced rather than compelling in either direction. The 21.8x forward PE versus 18.8x trailing signals the market expects EPS normalization, while the +9.3% implied upside to the $279.41 average target is modest for a buy-rated stock. The low beta of 0.206 and 2.46% dividend yield make it a stabilizing portfolio holding, but the 5.35x PS and 6.18x price-to-book leave little room for multiple expansion. I would upgrade to bullish if oncology growth accelerates enough to offset Stelara erosion and MedTech recovers, or if the stock pulls back toward the $230s; I would downgrade to bearish if revenue growth slips below 4% or a major litigation charge coincides with a guidance cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $279.41 and implied upside of +9.3% versus the current price.
Average Target
$279.41
0 analysts
Implied Upside
+9.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $320
Analyst target range
Coverage is deep, with 22 analysts and a consensus recommendation of "buy" (mean rating 1.91 on a 1-5 scale where 1 is strong buy). The average target price of $279.41 implies roughly +9.3% upside from the current $255.56, a moderate rather than aggressive bullish stance that reflects the stock's already-strong 33% one-year run. Recent institutional actions are uniformly constructive — UBS, HSBC, Guggenheim, Wells Fargo, Morgan Stanley, RBC, and Raymond James all reiterated Buy/Overweight/Outperform ratings between July and September 2026, with only JP Morgan maintaining a Neutral stance on September 29 — indicating stable conviction rather than a wave of upgrades. The target range is wide, from $190 to $320: the $320 high assumes successful oncology pipeline execution, MedTech recovery, and multiple expansion toward the mid-20s, while the $190 low discounts biosimilar erosion in immunology, continued MedTech weakness, and litigation overhang. The $130 spread (roughly 46% of the current price) signals meaningful uncertainty around pipeline and legal outcomes, though the clustering of reiterated Buy ratings and the modest +9% implied upside suggest analysts see the stock as fairly valued with defensive merit rather than a high-conviction bargain at current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: JNJ Investment Factors
The bull case currently holds the stronger evidence: JNJ has beaten the S&P 500 by 17.5 percentage points over one year with a beta of only 0.206, carries a fortress balance sheet (0.59 debt-to-equity, 25x interest coverage), and has repeatedly raised guidance on the back of oncology-led Innovative Medicine growth. The bear case is real but secondary — premium valuation (18.8x trailing, 21.8x forward), MedTech softness, and Stelara biosimilar erosion are headwinds to the pace of growth rather than threats to the franchise. The single most important tension is whether the oncology and pipeline ramp can outrun immunology biosimilar erosion and MedTech weakness fast enough to sustain mid-single-digit revenue growth; if it can, the premium multiple is justified, but if revenue growth slips toward low single digits, the 21.8x forward PE leaves little cushion. Near-term momentum (-4.4% in a month, relative strength -5.6) suggests the market is already discounting some of this risk, which modestly improves the risk/reward for patient investors.
Bullish
- Defensive outperformance with low beta: JNJ has gained 33.0% over the past year versus 15.5% for the S&P 500, and 23.3% YTD versus 11.9%, all while carrying a beta of just 0.206. That combination of market-beating returns and roughly 80% less volatility than the index is rare and supports the stock's role as a core defensive compounder.
- Raised guidance and oncology momentum: Management raised full-year sales guidance again after Q3, with consensus now modeling ~$135.4 billion in revenue. Innovative Medicine generated $16.38 billion (about 65% of Q2 sales), and recent coverage highlights booming oncology as the key growth driver toward a $100 billion annual revenue path.
- Fortress balance sheet and dividend: Debt-to-equity is only 0.59, interest coverage is roughly 25x ($7.17 billion operating income against $281 million quarterly interest), and trailing free cash flow of $18.71 billion comfortably covers the $3.23 billion quarterly dividend (46.2% payout). The 2.46% yield comes with a 64-year dividend increase streak.
- Improving margins and ROE: Operating margin recovered from 22.8% in Q4 2025 to 28.3% in Q2 2026, gross margin held in the 66-70% band, and trailing net margin is 28.5%. ROE of 32.9% is exceptional for the sector and reflects genuine operating leverage rather than one-time items.
Bearish
- Premium valuation limits multiple expansion: At 18.8x trailing PE and 5.35x PS, JNJ trades at a roughly 20-30% premium to the mid-teens multiple typical of drug manufacturers. The forward PE of 21.8x exceeds the trailing 18.8x, implying the market expects EPS to normalize lower rather than grow, which caps re-rating potential.
- MedTech weakness and sales miss: Q3 delivered an earnings beat but a revenue miss, driven by MedTech softness, and the stock fell on the report. MedTech contributed only $8.93 billion of Q2's $25.31 billion, so the segment is a persistent drag on the consolidated mid-single-digit growth story.
- Biosimilar erosion in immunology: Stelara biosimilar competition is explicitly cited as a threat in recent coverage, and the $190 analyst low target discounts continued immunology erosion. With Innovative Medicine at 65% of sales, even modest share loss in immunology has an outsized impact on consolidated revenue growth.
- Litigation overhang and thin liquidity: Persistent litigation costs are flagged as a reason for patience, and the current ratio of 1.03 is thin for a company returning $5.2 billion of debt and $3.2 billion of dividends in a single quarter. Legal charges have historically created earnings volatility, as seen in the Q4 2024 EPS of $1.41 versus $4.54 in Q1 2025.
JNJ Technical Analysis
J&J is in a sustained uptrend that has recently stalled into consolidation: the stock is up 33.0% over the past year and 23.3% year-to-date, materially outperforming the S&P 500's 15.5% and 11.9% respective gains. At $255.56, the shares sit roughly 90.9% of the way through their 52-week range of $184.66 to $281.07 — near but not at the highs, implying the stock retains upside room while carrying some overextension risk after a strong run. The 6-month gain of 9.1% confirms the intermediate trend remains constructive despite the recent wobble. Short-term momentum has clearly decelerated: the stock is down 4.4% over the past month versus a 1.2% gain for SPY, producing a relative strength reading of -5.6, and the 3-month change of just +1.0% badly lags SPY's +2.7% (relative strength -1.7). This divergence — a strong 1-year trend against a negative 1-month move — is consistent with a post-earnings pullback and mean reversion rather than a trend reversal, particularly given the stock's very low beta of 0.206, which implies roughly 80% less volatility than the market and makes sharp drawdowns unusual. Key support sits at the 52-week low of $184.66, with nearer-term support around the recent $248-249 area touched on October 13; resistance is defined by the 52-week high of $281.07 and the September peak near $278.43. A breakout above $281 would confirm resumption of the primary uptrend, while a breakdown below $248 would signal deeper consolidation toward the $230s; the maximum drawdown of -10.96% and low beta argue for modest position-sizing adjustments rather than aggressive hedging.
Beta
0.21
0.21x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$185-$281
Price range past year
Annual Return
+33.0%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | +0.2% |
| 3m | +1.0% | +2.9% |
| 6m | +9.1% | +8.4% |
| 1y | +33.0% | +14.9% |
| ytd | +23.3% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue is growing at a solid mid-single-digit pace: Q2 2026 revenue of $25.31 billion rose 6.6% year-over-year from $23.74 billion, extending a steady climb from $24.56 billion in Q4 2025 and $24.06 billion in Q1 2026. The segment mix shows Innovative Medicine at $16.38 billion (roughly 65% of sales) versus MedTech at $8.93 billion, meaning the pharmaceutical franchise is the primary growth engine while MedTech weakness — cited in recent coverage — is the drag. Analyst consensus projects full-year revenue of approximately $135.4 billion, implying continued mid-single-digit expansion, a trajectory that supports the investment case as a durable compounder but limits the multiple expansion typically reserved for high-growth names. Profitability is robust and improving: Q2 2026 net income was $5.53 billion on a 68.2% gross margin and 28.3% operating margin, with net margin of 21.9% in the quarter and 28.5% on a trailing basis. Gross margin has been stable in the 66-70% band across recent quarters (Q1 2026: 66.3%, Q4 2025: 67.6%, Q3 2025: 69.6%), while operating margin recovered from 22.8% in Q4 2025 to 28.3% in Q2 2026, reflecting operating leverage and lower one-time charges; EPS of $2.27 in Q2 2026 compares favorably with $2.14 in Q1 and $2.10 in Q4 2025. The balance sheet is conservatively managed: debt-to-equity of 0.59, current ratio of 1.03, and trailing free cash flow of $18.71 billion comfortably fund the $3.23 billion quarterly dividend (payout ratio 46.2%, yield 2.46%) plus capex of $1.32 billion in Q2. ROE of 32.9% is exceptional for the sector, and interest coverage of roughly 25x (Q2 interest expense $281 million against $7.17 billion operating income) underscores minimal financial risk; the main caveat is a thin current ratio of 1.03 and heavy quarterly capital returns ($5.2 billion debt repayment and $3.2 billion dividends in Q2) that leave less cushion than the headline FCF suggests.
Quarterly Revenue
$25.3B
2026-06
Revenue YoY Growth
+6.6%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Because J&J is solidly profitable (Q2 2026 net income of $5.53 billion), the PE ratio is the appropriate primary metric: the stock trades at 18.8x trailing earnings versus 21.8x forward earnings, an unusual structure in which the forward multiple exceeds the trailing one, implying the market expects EPS to normalize lower (likely reflecting one-time gains in the trailing base) rather than grow. On a trailing basis, 18.8x is modest for a healthcare leader, while the forward 21.8x against consensus EPS of $17.70 suggests the market is pricing steady but unspectacular growth. Relative to the broad drug-manufacturer peer group, J&J's 18.8x trailing PE and 5.35x PS sit at a premium to the sector's typical mid-teens multiple, a spread of roughly 20-30% that is justified by its AAA balance sheet, 2.46% dividend yield, 28.5% net margin, and 32.9% ROE — all well above industry norms — though the premium limits room for multiple expansion. Against its own history, the current 18.8x trailing PE is below the 24.7x recorded at Q4 2025 and the 28.5x at Q2 2026 in the historical ratio series, placing it in the lower half of its multi-year band (which has ranged from roughly 9x to 36x on a quarterly basis), while the 6.18x price-to-book is above the 4.7-5.6x levels seen through much of 2025. The read-through is that the stock is not priced for perfection on earnings but is priced richly on book value, suggesting the market is capitalizing stable cash flows rather than anticipating a re-rating.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on growth dependence and segment concentration. Innovative Medicine is roughly 65% of sales ($16.38 billion of $25.31 billion in Q2 2026), so immunology biosimilar erosion — particularly Stelara — can move the consolidated top line even if oncology performs. Revenue growth is only 6.6% year-over-year, meaning the 21.8x forward PE requires steady execution with little room for a miss, and the thin current ratio of 1.03 leaves limited liquidity cushion against the $5.2 billion debt repayment and $3.2 billion dividend paid in Q2 alone. Earnings quality is also uneven: Q4 2024 EPS was $1.41 versus $4.54 in Q1 2025, reflecting one-time items and litigation charges that make quarterly comparisons noisy.
Market and competitive risks are dominated by valuation compression and biosimilar competition. At 18.8x trailing and 21.8x forward earnings, JNJ trades at a 20-30% premium to the mid-teens sector multiple, and the unusual structure of forward PE exceeding trailing PE implies the market expects EPS to normalize lower. A beta of 0.206 limits macro-driven drawdowns, but it also means the stock will not benefit much from a broad risk-on rotation; instead, sector rotation out of defensives and into higher-growth healthcare names is the bigger threat. Recent coverage explicitly frames UnitedHealth as the better post-Q3 buy versus J&J's mixed results and premium valuation, and Stelara biosimilar competitors are gaining ground, which could pressure both revenue and the multiple simultaneously.
The worst-case scenario is a chain in which Stelara biosimilar erosion accelerates, MedTech weakness persists through 2027, and a major litigation charge lands in the same quarter — forcing a guidance cut and analyst downgrades that compress the multiple toward the sector mid-teens. From the current $255.56, a re-rating to 15x forward EPS of $17.70 would imply roughly $265, but applying the analyst low target of $190 represents about -26%, and a full retracement to the 52-week low of $184.66 would be roughly -28%. The historical max drawdown of -10.96% is a poor guide to tail risk given the stock's recent 33% run; a realistic adverse outcome is a -15% to -28% decline toward the $184-$217 range.
FAQ
The most severe risk is biosimilar erosion in immunology, particularly Stelara, which threatens the Innovative Medicine segment that generates 65% of sales ($16.38 billion of $25.31 billion in Q2). Second is valuation compression: at 21.8x forward earnings versus a mid-teens sector multiple, any growth disappointment could force a re-rating toward the $190 analyst low target, about -26% from current levels. Third is operational — MedTech weakness already caused a Q3 revenue miss, and the thin 1.03 current ratio leaves limited liquidity cushion against $5.2 billion of quarterly debt repayment and $3.2 billion of dividends. Fourth is litigation overhang, which has historically created earnings volatility (Q4 2024 EPS of $1.41 versus $4.54 in Q1 2025) and remains an unquantified tail risk. Ranked by severity: biosimilar erosion, valuation compression, MedTech execution, then litigation.
The 12-month forecast has three scenarios: a 55% probability base case of $265-$285, aligned with the $279.41 analyst average target, assuming ~6% revenue growth and stable 28% operating margins; a 25% probability bull case of $281-$320, driven by oncology pipeline execution and MedTech recovery toward the analyst high target; and a 20% probability bear case of $190-$230, driven by accelerated Stelara erosion, a litigation charge, and multiple compression toward the analyst low target. The base case is most likely because consensus revenue of $135.4 billion and EPS of $17.70 are already well-supported by Q2's 6.6% growth and 28.3% operating margin. The key assumption is that Innovative Medicine growth continues to offset MedTech softness and immunology erosion.
JNJ looks fairly valued to modestly rich. At 18.8x trailing earnings the stock is below its own historical range (24.7x at Q4 2025, 28.5x at Q2 2026, with a multi-year band of roughly 9x-36x), but the 21.8x forward PE exceeds the trailing multiple, implying the market expects EPS to normalize lower rather than grow. Relative to drug manufacturers trading at mid-teens multiples, JNJ's 18.8x PE and 5.35x PS represent a 20-30% premium justified by its AAA balance sheet, 28.5% net margin, and 32.9% ROE. The 6.18x price-to-book is above the 4.7-5.6x levels seen through much of 2025, suggesting the market is capitalizing stable cash flows rather than anticipating a re-rating. Net, the market is paying a fair-to-full price for quality, with limited room for multiple expansion.
From a risk/reward perspective, JNJ is a reasonable but not compelling buy at $255.56. The stock offers only +9.3% upside to the $279.41 average analyst target despite a buy consensus (mean 1.91 from 22 analysts), and it has already returned 33.0% over the past year. The biggest downside risk is a re-rating toward the $190 analyst low target (about -26%) if Stelara biosimilar erosion and MedTech weakness persist. However, the 0.206 beta, 2.46% dividend yield, and 32.9% ROE make it a low-volatility holding with limited permanent-capital risk. It is a good buy for income-oriented, long-term investors or those seeking defensive ballast, and a better buy on a pullback toward the $230s where the forward PE would compress toward 13x.
JNJ is best suited to long-term holding, with a suggested minimum horizon of three to five years. Its 0.206 beta means roughly 80% less volatility than the market, so short-term trading offers little edge — the stock's 4.4% one-month decline and 1.0% three-month gain illustrate how slowly it moves. The investment case is built on a 2.46% dividend yield with a 64-year increase streak, a 46.2% payout ratio, and 32.9% ROE, all of which compound over years rather than quarters. Earnings visibility is high given $18.71 billion in trailing free cash flow and a $135.4 billion consensus revenue base, but the 21.8x forward PE limits near-term multiple expansion. Short-term traders should look elsewhere for volatility; long-term income and defensive investors are the natural holders.